Peptide · Fact sheet
Survodutide
Also known as BI 456906
Survodutide is not FDA approved. Phase 2 and Phase 3 trials have reported weight loss, reduced liver fat, and MASH-resolution signals, while fibrosis outcomes, longer-term benefits, safety, and regulatory decisions remain under study.
What is Survodutide?
Survodutide is a manufactured peptide that activates both the glucagon and GLP-1 receptors.
The dual design aims to combine appetite and glucose effects with glucagon-related energy and liver biology, but mechanistic breadth can also create tradeoffs.
Benefits people look for
It is among the most advanced dual glucagon/GLP-1 candidates for obesity and metabolic liver disease.
Phase 3 liver-fat results strengthen the human evidence without turning an investigational program into an approved medicine.
What the evidence supports
- A Phase 2 obesity trial reported substantial average weight reduction compared with placebo.
- MASH and MASLD trials reported favorable resolution or liver-fat endpoints, while fibrosis and long-term clinical outcomes require further evidence.
All research areas
- Obesity
- Metabolic dysfunction-associated steatohepatitis
- Liver fat and fibrosis
- Type 2 diabetes
- Chronic weight management
- MASH and MASLD
- Obesity with or without type 2 diabetes
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
No attributable personal reports are summarized here yet. The benefits above describe research interests; the side effects below come from the cited medical sources.
We do not fill this gap with unsourced testimonials or estimated success rates.
Side effects & risks
- Gastrointestinal adverse effects were the most frequent treatment-emergent problems in trials.
- Discontinuation and incomplete exposure complicate estimates of real-world benefit.
- Long-term glucagon-receptor effects and uncommon harms remain under study.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Moderate human evidenceRandomized Phase 2 studies and a Phase 3 MASLD study report meaningful weight and liver-fat effects. Those endpoints do not yet establish broad liver-outcome, cardiovascular, or long-term clinical benefit.
Selected research to read
Controlled human study of body-weight efficacy, tolerability, and adverse events.
Biopsy-based MASH and fibrosis study with condition-specific endpoints.
Phase 3 liver-fat and body-weight trial with limited duration and geography.
Official Phase 3 obesity-study record and endpoint definitions.
FDA approval & research status
Survodutide remains investigational in the United States and is being evaluated in Phase 3 obesity and metabolic liver-disease programs.
No FDA-approved use is documented in the records summarized on this page.
Late-stage obesity and liver-disease research
Survodutide has Phase 3 trial evidence and registry records, but it remains investigational until an FDA review supports approval for a defined use.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- Whether liver-fat and MASH-resolution changes translate into fewer liver complications
- Long-term cardiovascular, gallbladder, pancreatic, and metabolic outcomes
- Durability of weight and liver effects
- Whether the benefit-risk profile will support FDA approval
The takeaway
Survodutide is a credible late-stage metabolic and liver candidate. Its trial results are promising, but approval and patient-centered long-term outcomes remain open questions.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1pubmedRandomized Phase 2 obesity trial
Controlled human study of body-weight efficacy, tolerability, and adverse events.
- 2pubmedRandomized Phase 2 MASH trial
Biopsy-based MASH and fibrosis study with condition-specific endpoints.
- 3pubmedSYNCHRONIZE-MASLD Phase 3 trial
Phase 3 liver-fat and body-weight trial with limited duration and geography.
- 4clinical trialsClinicalTrials.gov: SYNCHRONIZE-1
Official Phase 3 obesity-study record and endpoint definitions.